Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.

Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes ...

In addition, TransCelerate executives and member organizations, such as Amgen, Eli Lilly, GSK, and more, will present 10 impactful sessions at the conference, addressing critical and relevant topics ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

January 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on ...